We studied 172 patients for development of ocular graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (allo-SCT) from 2002 to 2009. Ocular GVHD was diagnosed in 60 patients (38%), with 27 (16%) being diagnosed at days 100 and 33 (23%) beyond day 100 for a 2-year cumulative incidence of 35% (95% confidence interval (CI), 28 --43). The positive and negative predictive values of a Schirmer I test score (using p5 mm as a cutoff) in predicting ocular GVHD (day 100) were 41 and 82%, respectively. In patients with ocular GVHD beyond day 100, extraocular manifestations of GVHD preceded the development of ocular GVHD in most patients (27 of 33, 81%). Prior acute skin GVHD (odds ratio 2.57, 95% CI 1.17 --5.64, P ¼ 0.019) and male recipients of female donors (odds ratio 2.57, 95% CI 1.09 --6.06, P ¼ 0.03) were independent risk factors for ocular GVHD. We recommend comprehensive ocular evaluation rather than a screening Schirmer's test to establish the diagnosis of ocular GVHD. Early diagnosis and preventive strategies in high-risk populations need to be studied in clinical trials to prevent devastating impact on quality of life in patients with prolonged ocular GVHD.
INTRODUCTION
Chronic graft-versus-host disease (GVHD) remains an important complication of allogeneic hematopoietic stem cell transplantation (allo-SCT). 1 --3 In 2005, the National Institute of Health (NIH) consensus criteria defined acute and chronic GVHD based on phenotype rather than temporal occurrence of GVHD after allo-SCT. 4 Ocular GVHD has been historically considered as 'extensive' GVHD and is primarily manifested as keratoconjunctivitis sicca (KCS). 5, 6 Ocular GVHD in addition can cause acute conjunctival inflammation, pseudomembranous and cicatrical conjunctivitis. KCS can occur in 40 --60% of patients with chronic GVHD. 7, 8 Left untreated, advanced ocular complications include corneal epithelial defects, corneal ulcers, secondary keratitis, perforation, stromal scarring, and loss of vision. 6,9 --11 The natural history of ocular GVHD suggested an incidence of 50% in transplant survivors, without any clear identification of risk factors. 12 In the NIH criteria, based on empiric consensus of experts, a mean Schirmer score p5 mm or new onset KCS with a Schirmer score of 6 --10 mm is sufficient for the diagnosis of ocular chronic GVHD in patients who have GVHD involving at least one other organ. 4 It is known that Schirmer's test is unreliable in normal volunteers and in patients with dry eye. 13 In a study of 75 dry eye patients examined by the same examiner on two different occasions, there was only moderate repeatability if the mean Schirmer value was o10 mm, and the repeatability was compromised further at values 410 mm. 14 Ogawa et al. 12 have studied ocular GVHD using both Schirmer's test and a comprehensive ocular examination. Using this method, the false positive rate diagnosis rate for dry eye due to chronic GVHD by Schirmer's test without nasal stimulation was 19.4% (6 of 31 cases) with the false negative rate representing 36.4% (8 of 22 cases).
Based on the above historical observations, all patients at our institute undergo a comprehensive ocular evaluation as part of their day 100 evaluation. In this study, we report the epidemiology of ocular GVHD in the context of the NIH consensus criteria and identify the risk factors associated with the development of ocular GVHD.
MATERIALS AND METHODS
All patients undergoing a comprehensive ocular evaluation at day 100 after their first allo-SCT (between January 2002 and December 2009) with subsequent follow-up in the long-term transplant clinic were included in this analysis. Patients signed an IRB (Institutional Review Board) approved data collection form before allo-SCT. Records were reviewed for ocular and non-ocular GVHD after allo-SCT until last follow-up, relapse or death. All patients received GVHD prophylaxis, management and supportive care as per institutional criteria or IRB approved protocols as described previously. 15 Between January 2002 and December 2009, 421 patients underwent allo-SCT at Vanderbilt University Medical Center, with an 89% day 100 survival (374 patients). Since February 2006, all patients more than 100 days after allo-SCT were followed in the long-term transplant clinic and systemic GVHD phenotype was prospectively classified based on the NIH criteria. Among patients undergoing allo-SCT between January 2002 and February 2006, subsets of patients were subsequently referred to longterm transplant clinic for follow-up. Patients from this group were included in the study cohort only if they had a day 100 ophthalmologic evaluation. In this subset, systemic GVHD was retrospectively classified based on the review of detailed clinical documentation by one reviewer (MJ). The final cohort consisted of 172 patients.
Comprehensive ocular examination at day 100 consisted of evaluation by an ocular surface expert (UT) and included best corrected visual acuity, intraocular pressure, full anterior segment slit-lamp examination, full dilated fundoscopic examination, Schirmer I, tear film instability, ocular surface disease index score, corneal and conjunctival staining. Conjunctival inflammation was diagnosed based on injection of palpebral and/or bulbar conjunctiva and mucous production. Subjective symptoms of KCS were assessed using ocular surface disease index questionnaire and patient's response to burning, foreign body sensation, tearing or grittiness. Corneal and conjunctival staining was done using one drop of fluorescein, which was instilled into the inferior cul de sac (done only by UT). This was allowed to sit for 3 min. Corneal and conjunctival staining was then observed with slit-lamp cobalt blue light. Patients were referred back to UT for worsening of symptoms or as part of a planned follow-up. Based on our experience, patients were diagnosed as having ocular GVHD if two of the following five criteria were met: new onset of subjective symptoms of KCS, tear film instability (defined as tear break up time p5 s), lacrimal insufficiency (Schirmer I p5 mm at 5 min), ocular surface abnormality (defined as vital staining grade I or higher) and presence of conjunctival inflammation.
Data regarding relapse, survival and cause of death were abstracted from electronic medical records.
Statistics
Descriptive statistics, including median and range for continuous variables, percentage and frequencies of categorical variables were calculated (Table 1) . Groups with nominal outcome were compared using w 2 -test; groups with continuous outcomes were compared using Wilcoxon rank sum test. Overall survival was calculated from onset of ocular of GVHD or from day 100 after allo-SCT in patients without ocular GVHD. Kaplan --Meir survival curves were calculated for the group(s) and were compared using the log rank test. 16 Cumulative incidence of ocular GVHD was calculated with death or relapse before ocular GVHD as a competing risk. 17 Multivariable analyses were performed using logistic regression (ocular GVHD as binary outcome) or Cox proportional hazard regression (ocular GVHD as a time to event). Analyses were performed using SPSS version 19 (IBM SPSS, Armonk, NY, USA) or R version 2.1.1 (Vienna, Austria). Table 1 summarizes the characteristics of all patients (N ¼ 172). Ocular GVHD developed in 60 patients (38%).
RESULTS
Ocular GVHD on day 100 evaluation Ocular GVHD was diagnosed as part of the day 100 evaluation in 27 patients (16%). The median Schirmer I test score for right and left eye at day 100 was 10 mm (range, 0 --35). Patients with ocular GVHD had a significantly lower Schirmer I test score (right eye, 7 mm (range, 0 --30); left eye, 7 mm (range, 0 --30)) compared with patients without ocular GVHD (right eye, 11 mm (range, 0 --35); left eye, 12 mm (range, 0 --35); P ¼ 0.02). Eleven patients (41%) with a Schirmer I test score of p5 mm had ocular GVHD. Twenty-six patients (18%) with a Schirmer I test score of p5 mm had no evidence of ocular GVHD. The false positive and false negative rates of the Schirmer I test score (using p5 mm as a cutoff) were 70 and 46%, respectively. The positive and negative predictive values of a Schirmer I test score in predicting ocular GVHD (day 100) were 41 and 82%, respectively. Ocular GVHD beyond day 100 after SCT Of the 145 patients without ocular GVHD at day 100 evaluation, 33 patients (23%) developed ocular GVHD at a median of 235 days (range, 100 --846) after allo-SCT. The median Schirmer I test score for right and left eyes in patients with ocular GVHD beyond day 100 was 8.5 mm (range, 0 --26). The cumulative incidence of ocular GVHD (day 100 or beyond) at 2 years after transplant was 35% (95% confidence interval (CI), 28 --43) (Figure 1) . Of the 33 patients who developed ocular GVHD beyond day 100, extraocular systemic GVHD was seen in 28 patients (85%). Twenty-seven patients (81%) experienced extraocular GVHD before the onset of ocular GVHD and only one patient developed extraocular GVHD after the onset of ocular GVHD. Five patients (15%) had no extraocular GVHD after day 100.
Outcome and risk factor analysis of ocular GVHD Median follow-up of the entire cohort is 13.3 months (range, 3.3 --97). The median survival (from day 100) of the entire cohort is not reached. The 2-year survival is 70.6%. Median survival of patients with ocular GVHD (measured from onset of ocular GVHD) was superior compared with patients without any ocular GVHD (measured from day 100) (70 months, 95% CI 60 --78 versus 56.3 months, 95% CI 47.1 --66, P ¼ 0.046) (Figure 2 ). Recipient gender, donor status, regimen intensity and disease risk did not influence survival. Of the 60 patients with ocular GVHD, acute GVHD (in first 100 days after allo-SCT) was seen in 49 (82%) patients. Among patients with acute GVHD (N ¼ 141), gastrointestinal GVHD as associated with an inferior survival compared with other subtypes (mean survival, 59 months; 95% CI 49.4 --68 versus 69 months; 95% CI 58.2 --78; P ¼ 0.046).
Univariate analysis
In univariate analyses, male gender was associated with a higher incidence of ocular GVHD (male 45% versus female 24%, P ¼ 0.004). In male recipients from female donors (n ¼ 38), the incidence of ocular GVHD was significantly higher (55%) compared with other donor-recipient gender combinations (29%) (P ¼ 0.003). Donor type, regimen intensity and disease risk did not influence incidence of ocular GVHD. Among patients with acute GVHD (n ¼ 141), skin involvement was associated with a higher incidence of ocular GVHD compared with non-skin acute GVHD (42 versus 23%, P ¼ 0.019).
Multivariate analysis
In multivariate analyses (logistic regression) (only patients with acute GVHD), prior acute skin GVHD (odds ratio 2.57, 95% CI 1.17 --5.64, P ¼ 0.019) and female donor to male recipient (odds ratio 2.57, 95% CI 1.09 --6.06, P ¼ 0.03) remained independent predictors of subsequent ocular GVHD. Using a Cox regression model, with event as time to ocular GVHD, female donor to male recipient (hazard ratio 2.24, 95% CI 1.31 --3.83) remained an independent predictor of ocular GVHD. Prior acute skin GVHD showed a trend towards significance (hazard ratio 1.65, 95% CI 0.98 --2.77, P ¼ 0.59).
DISCUSSION
This study highlights several important aspects of ocular GVHD, including the poor accuracy of the Schirmer test as a means to diagnose ocular GVHD. The day 100 incidence of ocular GVHD in this study was 16% and suggests that patients should undergo a comprehensive ocular examination at day 100 rather than a 'screening' Schirmer's test. The Schirmer test has been used as the gold standard for diagnosis of ocular GVHD. In view of previous observations of the poor reliability of the Schirmer test 13 and the confirmatory findings in this study, a revision of this particular criterion in the NIH classification may be needed. More recently, the German-Austrian-Swiss group has outlined consensus criteria for diagnosis and management of ocular GVHD, which remains to be validated, but realizes the limitation of the NIH criteria. 18 The NIH consensus criteria have developed a scoring system for various clinical domains of chronic GVHD. Each domain is scored from 0 to 3, reflecting no involvement to severe manifestations in the clinical domain ( Table 2 ). It has been proposed that these measures can be used as response criteria. Inamoto et al. 19 evaluated 387 patients (4% children) with chronic GVHD and correlated changes in several assessment tools (NIH eye score, patient-reported global rating of eye symptoms, Lee eye subscale, ocular surface disease index and Schirmer's test) in 333 follow-up visits where both provider and patient reported eye involvement at the previous visit. Agreement between patient and provider was only fair (weighted k 0.34). All scales except the Schirmer test correlated with both provider-reported and patient-reported changes in ocular chronic GVHD activity. Among all scales tested, changes in the NIH eye scores showed the greatest sensitivity to symptom change reported by providers or patients. The authors concluded that the Schirmer test should not be used as a response measure for ocular chronic GVHD. Thus, data indicate or support the view that Schirmer's test is not helpful either in diagnosis or as a response measure.
In agreement with our findings, Kamoi et al. 20 have recently reported a higher risk of ocular GVHD and more severe ocular GVHD in male patients receiving stem cells from female donors. This finding is consistent with prior reports of a higher incidence of chronic GVHD in transplants from female donors into male recipients. 21 --24 In this study, prior acute skin GVHD was an independent predictor of subsequent ocular GVHD, similar to a recent report. 25 In this study, the incidence of ocular GVHD was bimodal, with 27 of 60 patients being diagnosed with ocular GVHD at day 100, and 33 patients being diagnosed at a median of 235 days after transplant. The immunological basis of either acute skin GVHD as a predictor of ocular GVHD or the bimodal incidence is uncertain. The most common manifestation of ocular GVHD is dry eye or KCS, resulting from lacrimal gland destruction from the allogeneic T cells. Patients report ocular fatigue, dry eye sensation, a foreign body sensation, ocular pain, photophobia, blurring, red eye, discharge, heavy eye feeling, dull sensation, difficulty in eye opening, epiphora and itchy sensation or a burning sensation. In most patients, KCS is permanent once it develops. In one study, none of the patients who developed KCS as part of GVHD had a return of tear function to normal despite 4 years of follow-up. 7 In another study, only 8% of patients had some improvement after a follow-up of 0.5 --3 years. 26 A more recent study suggests that the response rate may be higher. In a cohort of 16 patients with ocular GVHD, 27 dry eye symptoms improved in 10 patients (62.5%), and corneal fluorescein staining improved in all eyes (P ¼ 0.0039). The value of ocular cyclosporine is being investigated in an ongoing randomized, double-masked, prospective study (http://www.clini caltrials.gov; NCT00755040) of ocular cyclosporine versus placebo.
Historically, the mainstay of therapy for patients with KCS due to GVHD has been the use of non-preserved artificial tears. Although this has been helpful in ameliorating the irritating symptoms of KCS, it does not address the ocular surface inflammation that is known to be present in this disease. Mechanical intervention with punctual plugging, nasolacrimal duct dilatation or cauterization can be used to control symptoms but again, does not address the inflammatory cascade that leads to KCS. 28 --30 More recently, the use of fluid-ventilated gas permeable scleral lenses have been reported to improve symptoms of ocular GVHD. 31 Immunosuppressive therapy in the form of ocular cyclosporine or steroids have been reported with variable success. 32, 33 Most patients with advanced KCS due to ocular GVHD continue to have residual symptoms despite the above interventions.
In summary, our study highlights the importance of aggressive comprehensive screening and preventive strategies needed to prevent most disturbing irreversible long-term complication after allo-SCT. Comprehensive ocular evaluation by a specialist rather than a screening Schirmer's test at day 100 after transplant is recommended to diagnose and optimally manage ocular GVHD. Further advances in the immunology of ocular GVHD are needed to understand the bimodal incidence of ocular GVHD.
